Clinical Trial: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE

U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07723976) titled 'A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE' on July 20.

Brief Summary: The efficacy, safety, and tolerability of CBD-OS have been evaluated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and Tuberous sclerosis complex (TSC). The current JZP926-303 study is being conducted to evaluate the safety and efficacy of CBD-OS in participants with Developmental and Epileptic Encephalopathy (DEE).

Study Start Date: Oct. 30, 2026

Study Type: INTERVENTIONAL

Condition: Developmental and Epi...